ReviewFrontiers in immunology2026
Distributed apoptotic checkpoints in B cell selection, tolerance, and autoimmunity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Generating a diverse B cell repertoire is essential for protective immunity, yet the required genetic alterations inevitably produce self-reactive, damaged, and non-competitive cells. To maintain immune homeostasis and ensure effective humoral immune responses, recent evidence supports the concept that a distributed network of apoptotic checkpoints operates at sequential stages of B cell development and activation. We discuss how these spatiotemporally distinct checkpoints collaborate with other tolerance mechanisms to regulate B cell selection and prevent systemic autoimmunity. Central tolerance mainly uses receptor editing to resolve high-avidity autoreactivity, while peripheral transitional B cell selection relies on B-cell activating factor and tonic B-cell receptor positive-selection signals, with cells failing to secure adequate signaling eliminated through apoptosis. Within germinal centers, apoptosis serves distinct functions in the dark and light zones, eliminating B cells damaged by somatic hypermutation and culling clones that fail to successfully acquire antigen and secure adequate T follicular helper cell help, respectively. We further discuss how extrafollicular responses provide a parallel, GC-independent pathway for autoreactive B-cell activation that is distinct from the stringent selection processes operating within germinal centers. Finally, we highlight evidence for an apoptosis-dependent process after activation that restricts the persistence of diversified autoreactive clones entering the memory B-cell and plasma-cell pools. Viewing B cell tolerance through the emerging conceptual framework of distributed apoptotic checkpoints may help explain how disruptions at distinct stages contribute to heterogeneous autoimmune pathologies and identify potential targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.